Protara (TARA) Director Gregory Sargen Receives 31,000-Share Award

What Happened
Gregory Sargen, a director of Protara Therapeutics, was granted 31,000 derivative shares on 2026-06-15. The grant was reported as $0 consideration (an award/derivative grant rather than a purchase). This is a non-sale transaction (an award), so it is not an open-market buy or sale.

Key Details

• Transaction type: Award/Grant (transaction code A) of 31,000 shares at $0.00 per share (derivative).
• Transaction date: 2026-06-15; Form 4 filed 2026-06-16 (appears timely).
• Vesting: Per the filing footnote, the shares vest in full on the first anniversary of the grant provided continuous board service, and will vest in full upon a Change of Control.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• No 10b5-1 plan, tax-withholding sale, or exercise/sale indicated — this was an award grant.

Context
An "A"/derivative award typically reflects a compensation grant (e.g., restricted stock or RSUs) for board service rather than an outright purchase or sale; such grants do not by themselves signal buying or selling intent. The vesting schedule means the shares are subject to forfeiture if the director leaves before the vest date, or may accelerate on a change of control.